Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma

Radiotherapy and Oncology

Volumn 95, Issue 3, 2010, Pages 359-364

  Sung, Chang Ohk ^a   Park, Won ^a   Choi, Yoon La ^a   Ahn, Geunghwan ^a   Song, Sang Yong ^a   Huh, Seung Jae ^a   Bae, Duk Soo ^b   Kim, Byoung Gie ^b   Lee, Je Ho ^b  

^a Department of Pathology ^*

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

CD24; Cervical carcinoma; Chemotherapy; Radiation therapy; Surgery

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P53; SOMATOMEDIN C RECEPTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RELAPSE; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; TISSUE MICROARRAY;

ADULT; AGED; ANTIGENS, CD24; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; UTERINE CERVICAL NEOPLASMS;

EID: 77952555805     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.01.007     Document Type: Article

References (39)

1. Waggoner S.E. Cervical cancer. Lancet 361 (2003) 2217-2225
2. Mathew A., and George P.S. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix - worldwide. Asian Pac J Cancer Prev 10 (2009) 645-650
3. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
4. Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., and Zaino R.J. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol 73 (1999) 177-183
5. Baykal C., Ayhan A., Al A., Yuce K., and Ayhan A. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 88 (2003) 123-129
6. Burri P., Djonov V., Aebersold D.M., et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 494-501
7. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48 (1998) 149-156
8. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
9. Huang L.W., Chou Y.Y., Chao S.L., Chen T.J., and Lee T.T. P53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol 83 (2001) 348-354
10. Kim G.E., Kim Y.B., Cho N.H., et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 10 (2004) 1366-1374
11. Kim T.J., Lee J.W., Song S.Y., et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 94 (2006) 1678-1682
12. Kim Y.B., Kim G.E., Cho N.H., et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95 (2002) 531-539
13. Lindel K., de Villiers E.M., Burri P., et al. Impact of viral E2-gene status on outcome after radiotherapy for patients with human papillomavirus 16-positive cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 65 (2006) 760-765
14. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., and West C.M. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83 (2000) 620-625
15. Pilch H., Gunzel S., Schaffer U., et al. The presence of HPV DNA in cervical cancer: correlation with clinico-pathologic parameters and prognostic significance. 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 11 (2001) 39-48
16. Suzuki Y., Nakano T., Kato S., Ohno T., Tsujii H., and Oka K. Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. Int J Radiat Oncol Biol Phys 60 (2004) 231-236
17. Lim S.C. CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 59 (2005) S351-S354
18. Agrawal S., Kuvshinoff B.W., Khoury T., et al. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg 11 (2007) 445-451
19. Choi Y.L., Lee S.H., Kwon G.Y., et al. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med 131 (2007) 275-281
20. Chou Y.Y., Jeng Y.M., Lee T.T., et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 14 (2007) 2748-2758
21. Fogel M., Friederichs J., Zeller Y., et al. CD24 is a marker for human breast carcinoma. Cancer Lett 143 (1999) 87-94
22. Karahan N., Guney M., Oral B., Kapucuoglu N., and Mungan T. CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur J Gynaecol Oncol 27 (2006) 500-504
23. Kim K.H., Choi J.S., Kim J.M., et al. Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol 24 (2009) 309-316
24. Kristiansen G., Denkert C., Schluns K., Dahl E., Pilarsky C., and Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161 (2002) 1215-1221
25. Kristiansen G., Schluns K., Yongwei Y., Denkert C., Dietel M., and Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88 (2003) 231-236
26. Kristiansen G., Winzer K.J., Mayordomo E., et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9 (2003) 4906-4913
27. Kwon G.Y., Ha H., Ahn G., Park S.Y., Huh S.J., and Park W. Role of CD24 protein in predicting metastatic potential of uterine cervical squamous cell carcinoma in patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 69 (2007) 1150-1156
28. Sano A., Kato H., Sakurai S., et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 16 (2009) 506-514
29. Choi Y.L., Yan H.X., Lee S.J., et al. Enhanced CD24 expression in colorectal cancer correlates with prognostic factors. Korean J Pathol 40 (2006) 103-111
30. Lee H.J., Kim D.I., Kwak C., Ku J.H., and Moon K.C. Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology 72 (2008) 603-607
31. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:263-64.
32. Sevin B.U., Lu Y., Bloch D.A., Nadji M., Koechli O.R., and Averette H.E. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. Cancer 78 (1996) 1438-1446
33. Inoue T., and Okumura M. Prognostic significance of parametrial extension in patients with cervical carcinoma stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation. Cancer 54 (1984) 1714-1719
34. Estape R.E., Angioli R., Madrigal M., et al. Close vaginal margins as a prognostic factor after radical hysterectomy. Gynecol Oncol 68 (1998) 229-232
35. Aigner S., Ruppert M., Hubbe M., et al. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 7 (1995) 1557-1565
36. Aigner S., Sthoeger Z.M., Fogel M., et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89 (1997) 3385-3395
37. Sammar M., Aigner S., and Altevogt P. Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta 1337 (1997) 287-294
38. Sammar M., Aigner S., Hubbe M., et al. Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol 6 (1994) 1027-1036
39. Aigner S., Ramos C.L., Hafezi-Moghadam A., et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 12 (1998) 1241-1251